Eiger Biopharmaceuticals (NASDAQ:EIGR) Stock Rating Reaffirmed by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH reiterated their buy rating on shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) in a report issued on Monday morning, AnalystRatings.com reports. LADENBURG THALM/SH SH currently has a $28.00 target price on the biotechnology company’s stock.

EIGR has been the topic of a number of other research reports. BidaskClub raised shares of Eiger Biopharmaceuticals from a sell rating to a hold rating in a report on Wednesday, October 30th. Zacks Investment Research lowered shares of Eiger Biopharmaceuticals from a buy rating to a hold rating in a research report on Friday, November 8th. Finally, ValuEngine cut shares of Eiger Biopharmaceuticals from a strong-buy rating to a buy rating in a report on Friday, November 8th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has an average rating of Buy and an average target price of $28.67.

Shares of NASDAQ EIGR traded down $0.09 during trading on Monday, reaching $11.48. 111,300 shares of the company traded hands, compared to its average volume of 158,714. The firm has a 50 day simple moving average of $10.61 and a 200-day simple moving average of $10.76. The company has a quick ratio of 6.83, a current ratio of 6.83 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $254.26 million, a PE ratio of -3.01 and a beta of 1.02. Eiger Biopharmaceuticals has a 52-week low of $8.40 and a 52-week high of $15.33.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.01). As a group, research analysts predict that Eiger Biopharmaceuticals will post -2.49 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in EIGR. Tocqueville Asset Management L.P. increased its position in Eiger Biopharmaceuticals by 5.6% in the third quarter. Tocqueville Asset Management L.P. now owns 36,175 shares of the biotechnology company’s stock worth $371,000 after buying an additional 1,925 shares in the last quarter. Bank of Montreal Can bought a new position in shares of Eiger Biopharmaceuticals in the second quarter worth about $28,000. Lindbrook Capital LLC bought a new position in shares of Eiger Biopharmaceuticals in the third quarter worth about $36,000. Tower Research Capital LLC TRC lifted its position in shares of Eiger Biopharmaceuticals by 1,719.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,895 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 4,626 shares in the last quarter. Finally, P.A.W. Capital Corp lifted its position in shares of Eiger Biopharmaceuticals by 5.3% during the 2nd quarter. P.A.W. Capital Corp now owns 200,000 shares of the biotechnology company’s stock valued at $2,120,000 after buying an additional 10,000 shares in the last quarter. 82.92% of the stock is owned by institutional investors and hedge funds.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Further Reading: Guidelines for Successful Channel Trading

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.